Lv61
1858 积分 2021-08-24 加入
Preclinical development of SL-325, a novel high-affinity DR3-blocking antibody for durable inhibition of the DR3/TL1A axis in inflammatory bowel disease
3天前
已完结
Mim8 Bispecific Antibody Prophylaxis in Hemophilia A with or without Inhibitors
19天前
已完结
Reducing affinity as a strategy to boost immunomodulatory antibody agonism
1个月前
已完结
A Rational Engineering Strategy for Designing Protein A-Binding Camelid Single-Domain Antibodies
2个月前
已完结
High-affinity omalizumab variants with optimized disruptive potency prevent anaphylaxis in vivo
3个月前
已完结
A trimer-disassembling anti-TL1A monoclonal antibody
3个月前
已完结
Molecular mechanism of IgE-mediated FcεRI activation
3个月前
已完结
Interleukin-33 in health and disease
3个月前
已完结
The superiority of MabSelect VL, Cytiva's second-generation Protein L resin, over three other affinity resins in purifying a VHH-containing trispecific antibody
4个月前
已完结
Dual-epitope targeting of TSLP to simultaneously block TSLPR and IL-7Rα with a Biparatopic nanobody
4个月前
已完结
皖公网安备34019202002308
